News | August 04, 2008

SpectraCell Offers Aspirin Response Testing

August 5, 2008 - SpectraCell Laboratories now offers Aspirin Response Testing (ART), designed to measure a person's response to low-dose aspirin therapy, which is routinely prescribed to millions of Americans for cardiovascular disease prevention.
Recent research has shown that the effects of aspirin in reducing blood (platelet) "stickiness" will vary considerably from patient to patient. Studies show that individuals who do not respond to aspirin (in reducing platelet stickiness) are more than three times more likely to die from heart disease than those that respond well to aspirin. ART will reportedly tell clinicians if aspirin therapy is working, while it also helps them determine the appropriate dosage of aspirin for each patient, allowing a doctor to tailor their recommendations to the individual.
Platelets are small blood cells that stick together to form blood clots and control bleeding. They produce a chemical called thromboxane to attract other platelets and increase their stickiness. Aspirin works by inhibiting the production of thromboxane by platelets, therefore reducing their stickiness and limiting the size of clots.
ART measures the level of thromboxane production in apparently healthy individuals. The enzyme-linked immunoassay (ELISA) measures the levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine. It reflects in vivo production of thromboxane A2, which is the target of aspirin therapy. Clinical studies such as the large HOPE (Heart Outcomes Prevention Evaluation) study have shown that elevated levels of 11dhTxB2 correlate to increased cardiovascular risk.
There are several reasons why a patient may not respond well to aspirin. It may be as simple as a patient taking a dose too low to effectively inhibit thromboxane A2 production. Platelets can also be activated by pathways that are not blocked by aspirin so other anti-thrombotic therapies may benefit patients that are resistant to aspirin for this reason.
Standard platelet function tests require freshly drawn blood and must be evaluated within four hours. However, since ART uses a random urine sample, it is not subject to variables associated with blood sampling. In addition, aspirin response is highly assay-specific, meaning that a patient may not test positive for aspirin resistance with tests that stimulate platelet aggregation in vitro via other, less specific pathways. ART is done in vivo and specifically measures stable thromboxane metabolites. The final results are reported in picograms of 11dhTxB2 per milligram of creatine to standardize results to urine concentration.
For more information: www.spectracell.com

Related Content

Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Canon Medical Systems introduces 33 MHz Ultra-High Frequency Ultrasound Transducer
News | Ultrasound Imaging | March 01, 2019
Expanding its advanced, high-performing Aplio i-series ultrasound platform Canon Medical Systems introduced what it...
Triton College Launching Vascular Technology in Sonography Certificate Program
News | Ultrasound Imaging | January 09, 2019
Starting in spring 2019, Triton College’s Vascular Technology in Sonography Certificate Program will help working...
Fujifilm SonoSite Launches New Point-of-Care Ultrasound Educational Resources
News | Ultrasound Imaging | November 01, 2018
Fujifilm SonoSite Inc. announced the launch of its redesigned SonoSite Institute, a comprehensive online educational...
Canon Medical Launches Healthy Sonographer Program
News | Ultrasound Imaging | October 10, 2018
Canon Medical Systems USA Inc. launched an all-new program designed to help reduce the leading causes of pain and...
Fujifilm SonoSite Unveils SonoSite Synchronicity Ultrasound Workflow Solution
Technology | Ultrasound Imaging | October 04, 2018
Fujifilm SonoSite Inc. announced its entry into the medical informatics space with the launch of a robust point-of-care...
GE Healthcare Expands Collaboration With SonoSim for Ultrasound Education
News | Ultrasound Imaging | October 02, 2018
October 2, 2018 — GE Healthcare announced an equity investment in SonoSim, which specializes in...
Clarius Reveals Wireless Cart-Based Ultrasound System at ACEP 2018
News | Ultrasound Imaging | September 28, 2018
Clarius Mobile Health is introducing the Clarius Cart at the American College of Emergency Physicians (ACEP) 2018...
Healcerion Receives FDA Approval for Sonon 300L Handheld Ultrasound Device
Technology | Ultrasound Imaging | July 09, 2018
South Korea-based Healcerion launched the Sonon 300L wireless handheld ultrasound device to the U.S. market following U...
Esaote Change of Ownership Completed
News | Ultrasound Imaging | April 30, 2018
The acquisition of biomedical equipment company Esaote SpA’s share capital was completed on April 19, the company...
Overlay Init